Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on: December 18,2023 11

Potential new treatment for angioimmunoblastic T-cell lymphoma

byUniversity of TsukubaCredit: AI-generated imageA type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from

Updated on:December 18,2023 11

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on: October 17,2023 290

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on:October 17,2023 290

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on: December 19,2023 23

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on:December 19,2023 23

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Updated on: December 18,2023 15

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Updated on:December 18,2023 15

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on: January 04,2024 9

As cancer deaths decline, access to care remains a challenge in some US communities

by Alex Osiadacz,Mayo ClinicCredit: Unsplash/CC0 Public DomainCancer remains the second-leading cause of death in the U.S., but the number of people dying from cancer continues to decline. In th

Updated on:January 04,2024 9

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on: October 24,2024 0

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on:October 24,2024 0

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023 6

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023 6

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023 63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023 63

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023 10

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023 10

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on: December 20,2023 12

One-cycle cisplatin seems safe for high-risk early testicular cancer

(HealthDay)—For high-risk stage 1 nonseminoma germ cell tumors of the testis (NSGCTT), one cycle of adjuvant bleomycin, etoposide (500 mg/m²), and cisplatin (BE500P) is safe, resulting in a two-year m

Updated on:December 20,2023 12

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on: October 14,2023 189

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on:October 14,2023 189